A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH DOCETAXEL WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER.

Trial Profile

A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH DOCETAXEL WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Docetaxel; LHRH receptor agonists; LHRH receptor antagonists; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms GETUG AFU 21; PEACE1
  • Most Recent Events

    • 12 Jan 2018 This trial has been suspended in Portugal.
    • 12 Dec 2017 Planned number of patients changed from 916 to 1168.
    • 12 Dec 2017 Planned End Date changed from 1 Oct 2023 to 1 Dec 2030.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top